RxDoctor Payments Data

Naresh Patel, DO

Allergy · Fort Wayne, INNPI 1063413052

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.3% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by GSK at 38.4% of the total.

$404in general payments, 2019–2025

Across 14 payments — averaging $28.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$155
  • ARS Pharmaceuticals Operations, Inc.$125
  • Aimmune Therapeutics, Inc.$27
  • AbbVie$25
  • Pfizer$23
  • Novartis$23
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$37793%
  • Education$277%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$433,903
Medicare patients
214
Services billed
14,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$54,267
XolairOmalizumab12$33,230
Breo ElliptaFluticasone/Vilanterol22$20,152
Arnuity ElliptaFluticasone Furoate27$9,075
Dexlansoprazole DrDexlansoprazole25$8,960
Famotidine233$3,454
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,322
Albuterol Sulfate HfaAlbuterol Sulfate77$2,213
Azelastine-FluticasoneAzelastine/Fluticasone13$1,894
Levocetirizine Dihydrochloride115$1,867
Mometasone Furoate27$1,424
Azelastine Hcl47$1,376
Pantoprazole Sodium133$1,334
Wixela InhubFluticasone Propion/Salmeterol14$1,083
Montelukast Sodium123$909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$155$83,494107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Indianaon file to place this against a meaningful peer group, so we don't.

Other allergy in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →